PS-341 or a combination of arsenic trioxide and interferon-α inhibit growth and induce caspase-dependent apoptosis in KSHV/ HHV-8-infected primary effusion lymphoma cells

Leukemia

Volumn 21, Issue 8, 2007, Pages 1792-1801

  Abou Merhi, R ^a   Khoriaty, R ^a   Arnoult, D ^b   El Hajj, H ^a   Dbouk, H ^a   Munier, S ^c   El Sabban, M E ^a   Hermine, O ^d   Gessain, A ^c   de The H ^e   Mahieux, R ^c   Bazarbachi, A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b HÔPITAL PAUL BROUSSE   (France)

^c INSTITUT PASTEUR   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BORTEZOMIB; CASPASE; CASPASE INHIBITOR; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL XL; RECOMBINANT ALPHA INTERFERON;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; LYMPHOCYTE PROLIFERATION; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION;

EID: 34447639790     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404797     Document Type: Article

References (63)

1. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
2. Ansari MQ, Dawson DB, Nador R, Rutherford C, Schneider NR, Latimer MJ et al. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol 1996; 105: 221-229.
3. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332: 1186-1191.
4. Cesarman E, Nador RG, Aozasa K, Delsol G, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities. Am J Pathol 1996; 149: 53-57.
5. Gessain A, Sudaka A, Briere J, Fouchard N, Nicola MA, Rio B et al. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: Is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 1996; 87: 414-416.
6. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86 1276-1280.
7. Carbone A, Gloghini A, Vaccher E, Cerri M, Gaidano G, Dalla-Favera R et al. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: A tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005; 7: 17-27.
8. Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004; 28: 1401-1416.
9. Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia 2005; 19: 851-855.
10. Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2003; 17: 785-820.
11. Carbone A, Gloghini A. AIDS-related lymphomas: From pathogenesis to pathology. Br J Haematol 2005; 130: 662-670.
12. Cesarman E. The role of Kaposi's sarcoma-associated herpesvirus (KSHV/ HHV-8) in lymphoproliferative diseases. Recent Results Cancer Res 2002; 159: 27-37.
13. Damania B, Jung JU. Comparative analysis of the transforming mechanisms of Epstein-Barr virus, Kaposi's sarcoma-associated herpesvirus, and Herpesvirus saimiri. Adv Cancer Res 2001; 80: 51-82.
14. Boulanger E, Duprez R, Delabesse E, Gabarre J, Macintyre E, Gessain A. Mono/oligoclonal pattern of Kaposi sarcoma-associated herpesvirus (KSHV/ HHV-8) episomes in primary effusion lymphoma cells. Int J Cancer 2005; 115: 511-518.
15. Drexler HG, Uphoff CC, Gaidano G, Carbone A. Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia 1998; 12: 1507-1517.
16. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003; 101: 1535-1542.
17. Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: Implications for therapy. J Virol 2007; 81: 1912-1922.
18. Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, Gutierrez MI et al. Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005; 11: 3102-3108.
19. Wang YF, Hsieh YF, Lin CL, Lin JL, Chen CY, Chiou YH et al. Staurosporine-induced G2/M arrest in primary effusion lymphoma BCBL-1 cells. Ann Hematol 2004; 83: 739-744.
20. Lee RK, Cai JP, Deyev V, Gill PS, Cabral L, Wood C et al. Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas. Cancer Res 1999; 59: 5514-5520.
21. Wu W, Rochford R, Toomey L, Harrington Jr W, Feuer G. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leuk Res 2005; 29: 545-555.
22. Ghosh SK, Wood C, Boise LH, Mian AM, Deyev VV, Feuer G et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood 2003; 101: 2321-2327.
23. Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007; 109: 2165-2173.
24. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: A single-institution study. J Clin Oncol 2003; 21: 3948-3954.
25. Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: Case report and literature review. AIDS Patient Care STDS 2004; 18: 67-73.
26. Boulanger E, Daniel MT, Agbalika F, Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003; 73: 143-148.
27. Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: Durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol 2006; 17: 1849-1850.
28. Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23: 4372-4380.
29. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436.
30. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96: 2537-2542.
31. Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 2003; 116: 3721-3728.
32. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 2002; 277: 13745-13751.
33. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004; 199: 993-1003.
34. Sanz MA, Fenaux P, Lo Coco F. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90: 1231-1235.
35. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
36. Warrell Jr RP, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177-189.
37. Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de The H, El-Sabban ME et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 2004; 5: 664-672.
38. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999; 93: 278-283.
39. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000; 96: 2849-2855.
40. Mahieux R, Hermine O. In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha. Leuk Lymphoma 2005; 46: 347-355.
41. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E et al. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001; 98: 3762-3769.
42. Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003; 101: 4576-4582.
43. Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004; 5: 130-134.
44. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638-2645.
45. Park DJ, Lenz HJ. The role of proteasome inhibitors in solid tumors. Ann Med 2004; 36: 296-303.
46. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
47. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003; 102: 303-310.
48. Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-1 associated adult T-cell leukemia/ lymphoma. Oncogene 2005; 24: 419-430.
49. Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood 2004; 104: 802-809.
50. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002; 62: 1083-1086.
51. Arvanitakis L, Mesri EA, Nador RG, Said JW, Asch AS, Knowles DM et al. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 1996; 88: 2648-2654.
52. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D et al. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 1996; 2: 342-346.
53. L as an inhibitor of cytosolic cytochrome c accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 1997; 94: 6939-6942.
54. Zhu Q, Zhang JW, Zhu HQ, Shen YL, Flexor M, Jia PM et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002; 99: 1014-1022.
55. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY et al. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 3978-3983.
56. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/ Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003; 88: 853-863.
57. Hideshima T, Richardson PG, Anderson KC. Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol 2003; 7: 191-204.
58. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
59. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
60. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9: 1145-1154.
61. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14: 1276-1283.
62. Alam A, Cohen LY, Aouad S, Sekaly RP. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J Exp Med 1999; 190: 1879-1890.
63. Olson NE, Graves JD, Shu GL, Ryan EJ, Clark EA. Caspase activity is required for stimulated B lymphocytes to enter the cell cycle. J Immunol 2003; 170: 6065-6072.